A short-term, multicenter, placebo-controlled, randomized withdrawal study of a metabotropic glutamate 2/3 receptor agonist using an electronic patient-reported outcome device in patients with schizophrenia.

14 Awad and Voruganti 15 detected a favorable trend on a number of such outcomes, demonstrating that interest is increasing in including patients’ reports in the management of their psychiatric conditions, and indicated that electronic technology should be quickly adopted by the field to bring about patient self-reports through remote electronic means to enable evaluation in real time, enhance recruitment, and reduce cost.

also in 993 other papers